A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MxA / myxovirus resistance protein A

[Related PubMed/MEDLINE]
Total Number of Papers: 132
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MxA  (>> Co-occurring Abbreviation)
Long Form:   myxovirus resistance protein A
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis. IFN-beta-1b, MRI, MS, SOCS3, USP18
2020 Evaluation of C-reactive protein and Myxovirus resistance protein A to guide rational use of antibiotics among acute febrile adult patients in Northwest Ethiopia. qCRP
2020 Interferon-beta exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. ---
2020 MicroRNA-21-3p modulates FGF2 to facilitate influenza A virus H5N1 replication by refraining type I interferon response. FGF-2, IAV, IFN, miR-21-3p, miRNAs, NP, OAS, PKR, qRT-PCR, RNA, TCID50
2020 Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies. DM, NXP-2
2020 Prevalence of respiratory viruses and antiviral MxA responses in children with febrile urinary tract infection. UTI
2020 Utility of the FebriDx point-of-care test for rapid triage and identification of possible coronavirus disease 2019 (COVID-19). COVID-19, CRP, NPV, POC
2019 Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases. ---
2019 Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. ASS, DM, MDA5, PFA, RIG-I
10  2019 Enterovirus infection and type 1 diabetes: unraveling the crime scene. EV, HLA-I, MDA5, PKR, RIG-I
11  2019 Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. CMAS, JDCBS, JDM, MSA
12  2019 FebriDx: A Rapid Diagnostic Test for Differentiating Bacterial and Viral Aetiologies in Acute Respiratory Infections. ARIs, CRP
13  2019 Human Antiviral Protein MxA Forms Novel Metastable Membraneless Cytoplasmic Condensates Exhibiting Rapid Reversible Tonicity-Driven Phase Transitions. ER, GFP, IFN, VSV
14  2019 Human Cervical Epithelial Cells Release Antiviral Factors and Inhibit HIV Replication in Macrophages. GBP5, HCEs, IFN, ISGs, MIP-1alpha, OAS-1, RANTES, SN, TLR
15  2019 Immunobiotic Strains Modulate Toll-Like Receptor 3 Agonist Induced Innate Antiviral Immune Response in Human Intestinal Epithelial Cells by Modulating IFN Regulatory Factor 3 and NF-kappaB Signaling. IECs, IFN-beta, IL-10, IL-1beta, IL-6, IL-8, IRF3, LAB, NF-kappaB, OSA1, RIG-I, TLR3, TNF-alpha
16  2019 Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. IFN, IP-10, iSLE
17  2019 Introducing a New Algorithm for Classification of Etiology in Studies on Pediatric Pneumonia: Protocol for the Trial of Respiratory Infections in Children for Enhanced Diagnostics Study. CAP, IRRID, TREND
18  2019 Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer. MHC-I, PDX
19  2018 A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. CRP, URIs
20  2018 Destabilized adaptive influenza variants critical for innate immune system escape are potentiated by host chaperones. ---
21  2018 Genomic Characterization of Lactobacillus delbrueckii TUA4408L and Evaluation of the Antiviral Activities of its Extracellular Polysaccharides in Porcine Intestinal Epithelial Cells. APS, EPS, IFN, IRF, NF-kappaB, PIE, TLR3
22  2018 Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population. CHC, CI, HCV, IFN, IL28B, OR
23  2018 Interferon-alpha-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells. CLEM, IFN
24  2018 Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activation. HCV, ISGs
25  2018 Neutralizing antibody production against Rebif and ReciGen in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability. EDSS, ELISA, IFN-beta, NAb, RRMS
26  2018 Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use. CRP, PCT, URI
27  2018 [Antiviral effects of IL-27 on HBV in HepG2.2.15 cells via inducing MxA by STAT1 signal transduction pathway]. HBcAg, HBV, IL-27, pSTAT1
28  2017 Aetiology of febrile pharyngitis in children: Potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection. GAS
29  2017 Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. IFNs, MHC, PD-L1, pSTAT1
30  2017 Detection of Host Response to Viral Respiratory Infection by Measurement of Messenger RNA for MxA, TRIM21, and Viperin in Nasal Swabs. TRIM21
31  2017 Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections. CRP, NPV, PPV, URIs
32  2017 Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers. HER2, HR, TILs, TLSs
33  2017 Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy. EDSS, IFN-beta, MS, RRMS
34  2017 Lateral flow immunoassay with upconverting nanoparticle-based detection for indirect measurement of interferon response by the level of MxA. LFIA, MS, UCNP
35  2017 MxA mRNA decrease preceding NAb detection in IFNbeta-treated MS patients. IFN-beta, MS, NAbs
36  2017 Myxovirus resistance protein A (MxA) polymorphism is associated with IFNbeta response in Iranian multiple sclerosis patients. MS
37  2017 Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta. NAbs
38  2017 Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis. MS
39  2017 Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. DM, MAC, PFA
40  2017 The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. DM, IFN, PM, SLE
41  2016 Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. MS
42  2016 IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. APOBEC, ISGs
43  2016 Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses. HCV, IL-23, PBMCs, qRT-PCR, RVR, SOCS3
44  2016 MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. HLA, IFNs, TILs, TNBC
45  2016 MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients. ---
46  2016 Plasmacytoid Dendritic Cells and Type I Interferon Signature in Lichen Striatus. LP, LS, pDCs
47  2016 Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infection. 2'-5'-OAS, Gal-9, HCV, IFN, PBMCs, SOCS1, Tim-3, TLR3
48  2015 Association of Myxovirus Resistance Gene Promoter Polymorphism with Response to Combined Interferon Treatment and Progression of Liver Disease in Chronic HCV Egyptian Patients. CI, HCV, IFN, OR
49  2015 Diagnosis of viral infections using myxovirus resistance protein A (MxA). AUC, ROC, Se, Sp
50  2015 Induction of interferon-lamda contributes to TLR3 and RIG-I activation-mediated inhibition of herpes simplex virus type 2 replication in human cervical epithelial cells. 5'ppp dsRNA, HSV-2, IFN-lamda, IRF3, ISG56, ISGs, NIDA, TLRs
51  2015 Oligomerization and GTP-binding Requirements of MxA for Viral Target Recognition and Antiviral Activity against Influenza A Virus. IAV, NP
52  2015 Structural analysis of tumor-related single amino acid mutations in human MxA protein. IFN, Mx1
53  2015 Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. CXCL10, DUSP1, HCV, ISG15, ISGs, LV-shDUSP1, OAS1, PEG-IFN, phosho-STAT1, USP18
54  2015 Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability. IFN-beta, MS, NAb, TPE
55  2014 Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. IFN-beta, MS, Mx1, NAbs
56  2014 Association of functional polymorphisms in the MxA gene with susceptibility to enterovirus 71 infection. EV71, ORs, PBMCs, PCR-RFLP
57  2014 Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PCR
58  2014 Hepatitis C virus impairs TLR3 signaling and inhibits IFN-lamda 1 expression in human hepatoma cell line. HCV, IFN, ISG56, JFH-1, NS, OAS-1, TLR3
59  2014 Immunological changes and increased expression of myxovirus resistance protein a in thyroid tissue of patients with recent onset and untreated Graves' disease. GD, pDCs
60  2014 Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. IFNs, ISGs, RSV
61  2014 Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. APOBEC, IFNs, IL-32
62  2014 MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. EIA, IFN, pSS
63  2014 MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. IFNbeta
64  2014 TRIM5alpha and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. CNS, PBMCs
65  2013 Endogenous IFNgamma in chronic HCV genotype 4 patients treated with PEG-IFNalpha and ribavirin. HCV, HCV-4, IFN-gamma, PEG-IFN, SNP
66  2013 IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. HBeAg, HBsAg, HBV, IL-17A, IL-17R, IL-22, IL-22R, OAS
67  2013 Intracellular RNA recognition pathway activates strong anti-viral response in human mast cells. IFIT3, MDA5, RIG-1
68  2013 Methamphetamine inhibits Toll-like receptor 9-mediated anti-HIV activity in macrophages. D1R, IFN, IRF7, METH, MyD88, TLR9
69  2013 MxA transcripts with distinct first exons and modulation of gene expression levels by single-nucleotide polymorphisms in human bronchial epithelial cells. IFN, ISRE, SNPs
70  2013 Myxovirus resistance gene A (MxA) expression suppresses influenza A virus replication in alpha interferon-treated primate cells. cRNA, gRNA, ISGs, RT-PCR, siRNA
71  2013 Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. HCV, IFN-alpha, PBMCs, TLR
72  2013 Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. HCV, HSC, IRF7, JFH, OAS-1, RIG-I, SN, TLR3
73  2013 The myxovirus resistance A (MxA) gene -88G>T single nucleotide polymorphism is associated with prostate cancer. ISRE
74  2013 Upregulation of innate antiviral restricting factor expression in the cord blood and decidual tissue of HIV-infected mothers. A3G, ART, CB, HEU, IFN, MNCs, TRIM-5alpha, UN
75  2013 Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-beta. CHMP, EMA, MS, NAbs
76  2012 Global secretome characterization of herpes simplex virus 1-infected human primary macrophages. HSV-1, IFIT2, STAT1
77  2012 Long-term beneficial effect of protease inhibitors on the intrinsic apoptosis of peripheral blood mononuclear cells in HIV-infected patients. 7-AAD, ART, Bax, Bcl-2, FasL, IFN-alpha, Nef, NNRTI, PIs, TRAIL
78  2012 MxA expression induced by alpha-defensin in healthy human periodontal tissue. HGECs, IFNs, OAS, PKR, SLPI
79  2012 Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. HCV, IFN, ISGs, PKR, SOCS3
80  2011 Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. huTRIM5alpha, IFN, IFNs, PBMCs, TRIM
81  2011 Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. IFN
82  2011 Interferon-inducible antiviral protein MxA enhances cell death triggered by endoplasmic reticulum stress. ER, TM
83  2011 MxA RNA quantification in febrile patients who underwent hematopoietic cell transplantation for primary immunodeficiency. ---
84  2010 A monoclonal antibody specific to human myxovirus resistance protein A. ---
85  2010 Activation of brain macrophages/microglia cells in hepatitis C infection. HCV, IFN, IL-1alpha, IP-10, TNF-alpha
86  2010 Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. 2',5'-OAS, IFN-beta, IFNARs, PKR, VSV
87  2010 Inhibition of interferon-alpha-induced signaling by hyperosmolarity and hydrophobic bile acids. IFN-alpha, PKR
88  2010 Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. 2',5'-OAS, 5-FU, IFNAR, MHC, Rb
89  2010 Lentivirus-mediated expression of MxA in chicken spermatogonial stem cells. EGFP, SSCs
90  2010 Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. BDCA-1, DC, DM, IFN, mDCs, pDCs
91  2010 Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study. CPE, IFN-beta, MMP-9, MS, NAbs, TRU
92  2010 Preparation of polyclonal antibody against human MxA protein and its specificity to diversified myxovirus resistant protein A. ---
93  2010 Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. MS, NAb
94  2010 Significance of the myxovirus resistance A (MxA) gene -123C>a single-nucleotide polymorphism in suppressed interferon beta induction of severe acute respiratory syndrome coronavirus infection. SARS, SNPs
95  2010 Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. CELs, CI, HR, MS
96  2009 Antibodies against interferon-beta in multiple sclerosis. bAb, IFN-beta, mRNA, NAb, PCR, RRMS
97  2009 Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. IFIT1, IFN-beta, MS, NAbs, s.c, TRU
98  2009 Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. IFN, MS, NAbs
99  2009 Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. CPE, IFN-beta, MS, NAb
100  2009 Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. IFN-beta, MS, NAb